Agios Pharmaceuticals (AGIO) Operating Expenses (2012 - 2026)
Agios Pharmaceuticals' (AGIO) quarterly Operating Expenses came in at $155.3 million in Q2 2026, up 11.32% YoY from $139.5 million in Q2 2025, and up 18.75% on a QoQ basis from $130.8 million in Q1 2026.
Agios Pharmaceuticals (AGIO) Operating Expenses (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals (AGIO) has 15 years of Operating Expenses data on file, last reported at $155.3 million in Q2 2026.
- Quarterly Operating Expenses rose 11.32% year-over-year to $155.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $557.4 million (up 10.94% YoY) and the FY2025 annual result came in at $526.2 million, up 13.83% from the prior year.
- Operating Expenses rose to $155.3 million in Q2 2026, from $130.8 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $155.3 million in Q2 2026 to a low of $94.6 million in Q3 2022.
- A 5-year average of $116.4 million and a median of $112.6 million in 2023 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses declined 5.64% — and 2025, when it advanced 21.92%.
- Tracing AGIO's Operating Expenses over 5 years: stood at $103.5 million in 2022, then rose by 9.56% to $113.4 million in 2023, then advanced by 19.75% to $135.8 million in 2024, then advanced by 4.26% to $141.5 million in 2025, then increased by 9.72% to $155.3 million in 2026.
- The last three Operating Expenses figures came in at $155.3 million (Q2 2026), $130.8 million (Q1 2026), and $141.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Agios Pharmaceuticals | 2.00 Bn | 1.38 Bn | 41.75 Mn | 155.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 155.30 Mn |
| Mar 31, 2026 | 130.77 Mn |
| Dec 31, 2025 | 141.55 Mn |
| Sep 30, 2025 | 129.75 Mn |
| Jun 30, 2025 | 139.51 Mn |
| Mar 31, 2025 | 115.36 Mn |
| Dec 31, 2024 | 135.77 Mn |
| Sep 30, 2024 | 111.78 Mn |
| Jun 30, 2024 | 114.43 Mn |
| Mar 31, 2024 | 100.26 Mn |
| Dec 31, 2023 | 113.38 Mn |
| Sep 30, 2023 | 108.30 Mn |
| Jun 30, 2023 | 100.41 Mn |
| Mar 31, 2023 | 96.22 Mn |
| Dec 31, 2022 | 103.48 Mn |
| Sep 30, 2022 | 94.61 Mn |
| Jun 30, 2022 | 103.22 Mn |
| Mar 31, 2022 | 101.98 Mn |
| Dec 31, 2021 | 104.83 Mn |
| Sep 30, 2021 | 91.15 Mn |